The US Food and Drug Administration's requirement for frequent echocardiogram monitoring of patients receiving Bristol Myers Squibb Company’s Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy (oHCM) should not be a barrier to the product’s commercial use, according to BMS executives.
BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
First-In-Class Drug’s List Price Is $89,500 Per Year
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
More from New Products
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The German group is paying $3.9bn to get hold of the US firm and its two approved products.
• By
Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.
More from Scrip
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies